AWM
VRTX icon

Abound Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Abound Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25K Sell
50
-26
-34% -$11.5K 0.01% 337
2026
Q1 		$34.1K Buy
76
+6
+9% +$2.8K 0.01% 308
2025
Q4 		$31.6K Hold
70
– – 0.01% 291
2025
Q3 		$27.3K Sell
70
-2
-3% -$836 0.01% 300
2025
Q2 		$31.9K Sell
72
-5
-6% -$2.3K 0.01% 266
2025
Q1 		$37.2K Sell
77
-16
-17% -$7.46K 0.01% 226
2024
Q4 		$37.3K Buy
93
+1
+1% +$464 0.01% 207
2024
Q3 		$42.7K Sell
92
-2
-2% -$961 0.01% 197
2024
Q2 		$43.9K Hold
94
– – 0.02% 164
2024
Q1 		$39.2K Buy
94
+1
+1% +$423 0.01% 170
2023
Q4 		$37.8K Buy
93
+43
+86% +$15.9K 0.02% 175
2023
Q3 		$17.4K Buy
50
+3
+6% +$1.05K 0.01% 235
2023
Q2 		$16.5K Buy
47
+11
+31% +$3.71K 0.01% 247
2023
Q1 		$11.3K Buy
36
+6
+20% +$1.8K 0.01% 273
2022
Q4 		$8.66K Buy
30
+15
+100% +$4.57K ﹤0.01% 280
2022
Q3 		$4.34K Buy
+15
New +$4.32K ﹤0.01% 379

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

Abound Wealth Management's VRTX Position: Q2 2026 in Review

Abound Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 34% in Q2 2026, selling an estimated $11.5K and leaving 50 shares worth $25K. The position accounts for 0.01% of the portfolio, ranked #337.

Abound Wealth Management first reported a position in VRTX in Q3 2022 and has held it in 16 quarters since. The position peaked at $43.9K in Q2 2024. 313 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Abound Wealth Management held 50 shares of Vertex Pharmaceuticals worth $25K as of Q2 2026.
  • Abound Wealth Management sold 26 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
  • Vertex Pharmaceuticals made up 0.01% of Abound Wealth Management's portfolio in Q2 2026, its #337 holding.
  • Abound Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Abound Wealth Management's Vertex Pharmaceuticals position peaked at $43.9K in Q2 2024.
  • 313 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.